Results 131 to 140 of about 54,075 (219)

Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates. [PDF]

World J Oncol
Zheng ZN, Ye XH, Shen XB, Li T, Guo J.
europepmc   +1 more source

Defining the tumor microenvironment of non‐small cell lung cancer

Immunology &Cell Biology, Volume 104, Issue 5, Page 499-518, May‐June 2026.
The tumor microenvironment (TME) in non‐small cell lung cancer is highly heterogeneous, both at a patient level and tumor microenvironment resolution. Defining the tumor microenvironment from patient‐responders and non‐responders will aid in the development of targeted therapeutics specific for each individual patient.
Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe   +5 more
wiley   +1 more source

Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload. [PDF]

ACS Omega
Manabe S, Senga S, Iwamoto S, Yarita H, Takahashi R, Mitani A, Sumiyoshi W, Hoshinoo A, Hiranyakorn M, Kinoshita T, Yoshimura C.   +10 more
europepmc   +1 more source

Advancements in targeted therapy for gastric cancer. [PDF]

Ther Adv Gastroenterol
Wang Y, Li J, Liu G, Zhang C, Li P, Kang W, Ye X.   +6 more
europepmc   +1 more source

Cancer Therapy-Related Cardiac Dysfunction, Risk Stratification, and Outcomes in ICOP Registry: First Data from the Arabian Middle East Region. [PDF]

Glob Heart
Farhan HA, Ali AA, Yaseen IF.
europepmc   +1 more source

The Synthesis and Anticancer Activity of the Trastuzumab-Doxorubicin Antibody-Drug Conjugate Using Strain-Promoted Alkyne-Azide Coupling. [PDF]

ACS Omega
Thakur SK, Ghosh R, Chauhan N, Guchhait P, Eswaran SV.   +4 more
europepmc   +1 more source

Anti-cancer effect of a novel photodynamic therapy using glucose-linked chlorin e6 conjugated trastuzumab for HER2-positive gastrointestinal cancers. [PDF]

PLoS One
Sasaki M, Tanaka M, Nomoto A, Yamasaki R, Yoshimura T, Yano S, Sasaki Y, Kojima Y, Suzuki T, Nishie H, Ozeki K, Shimura T, Kubota E, Kataoka H.   +13 more
europepmc   +1 more source

AXL-Driven Stemness and Hedgehog Signaling in HER2-Positive Breast Cancer with Acquired Trastuzumab Resistance: Synergistic Potential of AXL and HER2 Co-Targeting. [PDF]

Life (Basel)
Boz AB, Er I, Picher EA, Smarakan S.
europepmc   +1 more source

Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023. [PDF]

Ther Adv Gastroenterol
Shimozaki K, Ooki A, Yoshikawa K, Yoshino K, Udagawa S, Osumi H, Fukuoka S, Wakatsuki T, Ogura M, Takahari D, Shinozaki E, Chin K, Yamaguchi K.   +12 more
europepmc   +1 more source

Recurrent severe thrombocytopenia induced by anti-HER2 therapy in a breast cancer patient with an underlying immune disorder: a case report and literature review. [PDF]

Front Oncol
Wang B, Chen L, Tang Q.
europepmc   +1 more source